Progress in nonviral gene therapy for breast cancer and what comes next?

References

• McCrudden CM, McCarthy HO. Current status of gene therapy for breast cancer: progress and challenges. Appl Clin Genet. 2014;7:209–220.
   PubMedGoogle Scholar
• Stoff-Khalili MA, Dall P, Curiel DT. Gene therapy for carcinoma of the breast. Cancer Gene Ther. 2006;13:633–647.
   PubMed Web of Science ®Google Scholar
• Yin H, Kanasty RL, Eltoukhy AA, et al. Non-viral vectors for gene-based therapy. Nat Rev Genet. 2014;15:541–555.
   PubMed Web of Science ®Google Scholar
• Sanchez-Rivera FJ, Jacks T. Applications of the CRISPR-Cas9 system in cancer biology. Nat Rev Cancer. 2015;15:387–395.
   PubMed Web of Science ®Google Scholar
• Chira S, Jackson CS, Oprea I, et al. Progresses towards safe and efficient gene therapy vectors. Oncotarget. 2015;6:30675–30703.
   PubMed Web of Science ®Google Scholar
• Lichty BD, Breitbach CJ, Stojdl DF, et al. Going viral with cancer immunotherapy. Nat Rev Cancer. 2014;14:559–567.
   PubMed Web of Science ®Google Scholar
• Gandhi NS, Tekade RK, Chougule MB. Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances. J Control Release. 2014;194:238–256.
   PubMed Web of Science ®Google Scholar
• Nastiuk KL, Krolewski JJ. Opportunities and challenges in combination gene cancer therapy. Adv Drug Deliv Rev. 2016;98:35–40.
   PubMed Web of Science ®Google Scholar
• Bottai G, Raschioni C, Székely B, et al. AXL-associated tumor inflammation as a poor prognostic signature in chemotherapy-treated triple-negative breast cancer patients. NPJ Breast Cancer. 2016. DOI:10.1038/npjbcancer.2016.33.
   Google Scholar
• Savas P, Salgado R, Denkert C, et al. Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol. 2016;13:228–241.
   PubMed Web of Science ®Google Scholar
• Bottai G, Raschioni C, Losurdo A, et al. An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers. Breast Cancer Res. 2016;18:121.
   PubMed Web of Science ®Google Scholar
• Pahle J, Walther W. Vectors and strategies for nonviral cancer gene therapy. Expert Opin Biol Ther. 2016;16:443–461.
   PubMed Web of Science ®Google Scholar
• Truffi M, Sorrentino L, Mazzucchelli S, et al. What is the role of nanotechnology in diagnosis and treatment of metastatic breast cancer? Promising scenarios for the near future. J Nanomater. 2016;2016:16.
   Google Scholar
• Cho K, Wang X, Nie S, et al. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res. 2008;14:1310–1316.
   PubMed Web of Science ®Google Scholar
• Vago R, Collico V, Zuppone S, et al. Nanoparticle-mediated delivery of suicide genes in cancer therapy. Pharmacol Res. 2016;111:619–641.
   PubMed Web of Science ®Google Scholar
• Dong D, Gao W, Liu Y, et al. Therapeutic potential of targeted multifunctional nanocomplex co-delivery of siRNA and low-dose doxorubicin in breast cancer. Cancer Lett. 2015;359:178–186.
   PubMed Web of Science ®Google Scholar
• Shen H, Mittal V, Ferrari M, et al. Delivery of gene silencing agents for breast cancer therapy. Breast Cancer Res. 2013;15:205.
   PubMed Web of Science ®Google Scholar
• Prabhakar U, Maeda H, Jain RK, et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res. 2013;73:2412–2417.
   PubMed Web of Science ®Google Scholar
• Gujrati M, Vaidya AM, Mack M, et al. Targeted dual pH-sensitive lipid ECO/siRNA self-assembly nanoparticles facilitate in vivo cytosolic sieIF4E delivery and overcome paclitaxel resistance in breast cancer therapy. Adv Healthc Mater. 2016. DOI:10.1002/adhm.201600677.
   Web of Science ®Google Scholar
• Hayward SL, Francis DM, Kholmatov P, et al. Targeted delivery of microRNA125a-5p by engineered lipid nanoparticles for the treatment of HER2 positive metastatic breast cancer. J Biomed Nanotechnol. 2016;12:554–568.
   PubMed Web of Science ®Google Scholar
• Parvani JG, Gujrati MD, Mack MA, et al. Silencing beta3 integrin by targeted ECO/siRNA nanoparticles inhibits EMT and metastasis of triple-negative breast cancer. Cancer Res. 2015;75:2316–2325.
   PubMed Web of Science ®Google Scholar
• Yu MZ, Pang WH, Yang T, et al. Systemic delivery of siRNA by T7 peptide modified core-shell nanoparticles for targeted therapy of breast cancer. Eur J Pharm Sci. 2016;92:39–48.
   PubMed Web of Science ®Google Scholar
• Devulapally R, Sekar NM, Sekar TV, et al. Polymer nanoparticles mediated codelivery of antimiR-10b and antimiR-21 for achieving triple negative breast cancer therapy. ACS Nano. 2015;9:2290–2302.
   PubMed Web of Science ®Google Scholar
• Elazar V, Adwan H, Bauerle T, et al. Sustained delivery and efficacy of polymeric nanoparticles containing osteopontin and bone sialoprotein antisenses in rats with breast cancer bone metastasis. Int J Cancer. 2010;126:1749–1760.
   PubMed Web of Science ®Google Scholar
• Devulapally R, Sekar TV, Paulmurugan R. Formulation of anti-miR-21 and 4-hydroxytamoxifen co-loaded biodegradable polymer nanoparticles and their antiproliferative effect on breast cancer cells. Mol Pharm. 2015;12:2080–2092.
   PubMed Web of Science ®Google Scholar
• Palanca-Wessels MC, Booth GC, Convertine AJ, et al. Antibody targeting facilitates effective intratumoral siRNA nanoparticle delivery to HER2-overexpressing cancer cells. Oncotarget. 2016;7:9561–9575.
   PubMed Web of Science ®Google Scholar
• Wu Y, Zhang Y, Zhang W, et al. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles. Colloids Surf B Biointerfaces. 2016;138:60–69.
   PubMed Web of Science ®Google Scholar
• Ren X, Liu L, Zhou Y, et al. Nanoparticle siRNA against BMI-1 with a polyethylenimine-laminarin conjugate for gene therapy in human breast cancer. Bioconjug Chem. 2016;27:66–73.
   PubMed Web of Science ®Google Scholar
• Bai M, Shen M, Teng Y, et al. Enhanced therapeutic effect of adriamycin on multidrug resistant breast cancer by the ABCG2-siRNA loaded polymeric nanoparticles assisted with ultrasound. Oncotarget. 2015;6:43779–43790.
   PubMed Web of Science ®Google Scholar
• Finlay J, Roberts CM, Lowe G, et al. RNA-based TWIST1 inhibition via dendrimer complex to reduce breast cancer cell metastasis. Biomed Res Int. 2015;2015:382745.
   PubMed Web of Science ®Google Scholar
• Yang H, Deng L, Li T, et al. Multifunctional PLGA nanobubbles as theranostic agents: combining doxorubicin and P-gp siRNA co-delivery into human breast cancer cells and ultrasound cellular imaging. J Biomed Nanotechnol. 2015;11:2124–2136.
   PubMed Web of Science ®Google Scholar
• Tekie FS, Atyabi F, Soleimani M, et al. Chitosan polyplex nanoparticle vector for miR-145 expression in MCF-7: optimization by design of experiment. Int J Biol Macromol. 2015;81:828–837.
   PubMed Web of Science ®Google Scholar
• Yin T, Wang L, Yin L, et al. Co-delivery of hydrophobic paclitaxel and hydrophilic AURKA specific siRNA by redox-sensitive micelles for effective treatment of breast cancer. Biomaterials. 2015;61:10–25.
   PubMed Web of Science ®Google Scholar
• Kaushal N, Durmaz YY, Bao L, et al. “Smart” nanoparticles enhance the cytoplasmic delivery of anti-RhoC silencing RNA and inhibit the migration and invasion of aggressive breast cancer cells. Mol Pharm. 2015;12:2406–2417.
   PubMed Web of Science ®Google Scholar
• Tang S, Yin Q, Su J, et al. Inhibition of metastasis and growth of breast cancer by pH-sensitive poly (beta-amino ester) nanoparticles co-delivering two siRNA and paclitaxel. Biomaterials. 2015;48:1–15.
   PubMed Web of Science ®Google Scholar
• Yhee JY, Song S, Lee SJ, et al. Cancer-targeted MDR-1 siRNA delivery using self-cross-linked glycol chitosan nanoparticles to overcome drug resistance. J Control Release. 2015;198:1–9.
   PubMed Web of Science ®Google Scholar
• Qian J, Xu M, Suo A, et al. Folate-decorated hydrophilic three-arm star-block terpolymer as a novel nanovehicle for targeted co-delivery of doxorubicin and Bcl-2 siRNA in breast cancer therapy. Acta Biomater. 2015;15:102–116.
   PubMed Web of Science ®Google Scholar
• Tangudu NK, Verma VK, Clemons TD, et al. RNA interference using c-Myc-conjugated nanoparticles suppresses breast and colorectal cancer models. Mol Cancer Ther. 2015;14:1259–1269.
   PubMed Web of Science ®Google Scholar
• Alinejad V, Hossein Somi M, Baradaran B, et al. Co-delivery of IL17RB siRNA and doxorubicin by chitosan-based nanoparticles for enhanced anticancer efficacy in breast cancer cells. Biomed Pharmacother. 2016;83:229–240.
   PubMed Web of Science ®Google Scholar
• Jadidi-Niaragh F, Atyabi F, Rastegari A, et al. Downregulation of CD73 in 4T1 breast cancer cells through siRNA-loaded chitosan-lactate nanoparticles. Tumour Biol. 2016;37:8403–8412.
   PubMed Web of Science ®Google Scholar
• Ding Y, Su S, Zhang R, et al. Precision combination therapy for triple negative breast cancer via biomimetic polydopamine polymer core-shell nanostructures. Biomaterials. 2017;113:243–252.
   PubMed Web of Science ®Google Scholar
• Yoo B, Kavishwar A, Ross A, et al. Combining miR-10b-targeted nanotherapy with low-dose doxorubicin elicits durable regressions of metastatic breast cancer. Cancer Res. 2015;75:4407–4415.
   PubMed Web of Science ®Google Scholar
• Zhou H, Wei J, Dai Q, et al. CaCO3/CaIP6 composite nanoparticles effectively deliver AKT1 small interfering RNA to inhibit human breast cancer growth. Int J Nanomedicine. 2015;10:4255–4266.
   PubMed Web of Science ®Google Scholar
• Hardie J, Jiang Y, Tetrault ER, et al. Simultaneous cytosolic delivery of a chemotherapeutic and siRNA using nanoparticle-stabilized nanocapsules. Nanotechnology. 2016;27:374001.
   PubMed Web of Science ®Google Scholar
• Rajput S, Puvvada N, Kumar BN, et al. Overcoming Akt induced therapeutic resistance in breast cancer through siRNA and thymoquinone encapsulated multilamellar gold niosomes. Mol Pharm. 2015;12:4214–4225.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Kennell C, Lee JY, et al. Calcium phosphate-polymer hybrid nanoparticles for enhanced triple negative breast cancer treatment via co-delivery of paclitaxel and miR-221/222 inhibitors. Nanomedicine. 2016. DOI:10.1016/j.nano.2016.07.016.
   Web of Science ®Google Scholar
• Khaled SZ, Cevenini A, Yazdi IK, et al. One-pot synthesis of pH-responsive hybrid nanogel particles for the intracellular delivery of small interfering RNA. Biomaterials. 2016;87:57–68.
   PubMed Web of Science ®Google Scholar
• Liu L, Li H, Zhang M, et al. Effects of targeted nano-delivery systems combined with hTERT-siRNA and Bmi-1-siRNA on MCF-7 cells. Int J Clin Exp Pathol. 2015;8:6674–6682.
   PubMed Web of Science ®Google Scholar
• Gu S, Hu Z, Ngamcherdtrakul W, et al. Therapeutic siRNA for drug-resistant HER2-positive breast cancer. Oncotarget. 2016;7:14727–14741.
   PubMed Web of Science ®Google Scholar
• Li T, Shen X, Chen Y, et al. Polyetherimide-grafted Fe3O4/@SiO2 nanoparticles as theranostic agents for simultaneous VEGF siRNA delivery and magnetic resonance cell imaging. Int J Nanomedicine. 2015;10:4279–4291.
   PubMed Web of Science ®Google Scholar
• Li M, Li Y, Huang X, et al. Captopril-polyethyleneimine conjugate modified gold nanoparticles for co-delivery of drug and gene in anti-angiogenesis breast cancer therapy. J Biomater Sci Polym Ed. 2015;26:813–827.
   PubMed Web of Science ®Google Scholar
• Arami S, Mahdavi M, Rashidi MR, et al. Novel polyacrylate-based cationic nanoparticles for survivin siRNA delivery combined with mitoxantrone for treatment of breast cancer. Biologicals. 2016. DOI:10.1016/j.biologicals.2016.09.005.
   PubMed Web of Science ®Google Scholar
• Shu D, Li H, Shu Y, et al. Systemic delivery of anti-miRNA for suppression of triple negative breast cancer utilizing RNA nanotechnology. ACS Nano. 2015;9:9731–9740.
   PubMed Web of Science ®Google Scholar
• Conde J, Oliva N, Atilano M, et al. Self-assembled RNA-triple-helix hydrogel scaffold for microRNA modulation in the tumour microenvironment. Nat Mater. 2016;15:353–363.
   PubMed Web of Science ®Google Scholar
• Subramanian N, Kanwar JR, Kanwar RK, et al. Targeting cancer cells using LNA-modified aptamer-siRNA chimeras. Nucleic Acid Ther. 2015;25:317–322.
   PubMed Web of Science ®Google Scholar
• Ozpolat B, Sood AK, Lopez-Berestein G. Liposomal siRNA nanocarriers for cancer therapy. Adv Drug Deliv Rev. 2014;66:110–116.
   PubMed Web of Science ®Google Scholar
• Li Y, Lee RJ, Yu K, et al. Delivery of siRNA using lipid nanoparticles modified with cell penetrating peptide. ACS Appl Mater Interfaces. 2016;8:26613–26621.
   PubMed Web of Science ®Google Scholar
• Talluri SV, Kuppusamy G, Karri VV, et al. Lipid-based nanocarriers for breast cancer treatment – comprehensive review. Drug Deliv. 2016;23:1291–1305.
   PubMed Web of Science ®Google Scholar
• Zuckerman JE, Davis ME. Clinical experiences with systemically administered siRNA-based therapeutics in cancer. Nat Rev Drug Discov. 2015;14:843–856.
   PubMed Web of Science ®Google Scholar
• Yao YD, Sun TM, Huang SY, et al. Targeted delivery of PLK1-siRNA by ScFv suppresses Her2+ breast cancer growth and metastasis. Sci Transl Med. 2012;4:130ra48.
   PubMed Web of Science ®Google Scholar
• Tang Z, He C, Tian H, et al. Polymeric nanostructured materials for biomedical applications. Prog Polym Sci. 2016;60:86–128.
   Web of Science ®Google Scholar
• Lee J, Chatterjee DK, Lee MH, et al. Gold nanoparticles in breast cancer treatment: promise and potential pitfalls. Cancer Lett. 2014;347:46–53.
   PubMed Web of Science ®Google Scholar
• Ekin A, Karatas OF, Culha M, et al. Designing a gold nanoparticle-based nanocarrier for microRNA transfection into the prostate and breast cancer cells. J Gene Med. 2014;16:331–335.
   PubMed Web of Science ®Google Scholar
• Guo P. The emerging field of RNA nanotechnology. Nat Nanotechnol. 2010;5:833–842.
   PubMed Web of Science ®Google Scholar
• Wang K, Huang Q, Qiu F, et al. Non-viral delivery systems for the application in p53 cancer gene therapy. Curr Med Chem. 2015;22:4118–4136.
   PubMed Web of Science ®Google Scholar
• Vidal SJ, Rodriguez-Bravo V, Galsky M, et al. Targeting cancer stem cells to suppress acquired chemotherapy resistance. Oncogene. 2014;33:4451–4463.
   PubMed Web of Science ®Google Scholar
• Lin S, Gregory RI. MicroRNA biogenesis pathways in cancer. Nat Rev Cancer. 2015;15:321–333.
   PubMed Web of Science ®Google Scholar
• Bottai G, Pasculli B, Calin GA, et al. Targeting the microRNA-regulating DNA damage/repair pathways in cancer. Expert Opin Biol Ther. 2014;14:1667–1683.
   PubMed Web of Science ®Google Scholar
• Paladini L, Fabris L, Bottai G, et al. Targeting microRNAs as key modulators of tumor immune response. J Exp Clin Cancer Res. 2016;35:103.
   PubMed Web of Science ®Google Scholar
• De Mattos-Arruda L, Bottai G, Nuciforo PG, et al. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients. Oncotarget. 2015;6:37269–37280.
   PubMed Web of Science ®Google Scholar
• Kleivi Sahlberg K, Bottai G, Naume B, et al. A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients. Clin Cancer Res. 2015;21:1207–1214.
   PubMed Web of Science ®Google Scholar
• Jung EJ, Santarpia L, Kim J, et al. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer. 2012;118:2603–2614.
   PubMed Web of Science ®Google Scholar
• Iorio MV, Casalini P, Piovan C, et al. Breast cancer and microRNAs: therapeutic impact. Breast. 2011;20(Suppl 3):S63–70.
   PubMed Web of Science ®Google Scholar
• Mann K, Kullberg M. Trastuzumab-targeted gene delivery to Her2-overexpressing breast cancer cells. Cancer Gene Ther. 2016;23:221–228.
   PubMed Web of Science ®Google Scholar
• Jiang K, Li J, Yin J, et al. Targeted delivery of CXCR4-siRNA by scFv for HER2(+) breast cancer therapy. Biomaterials. 2015;59:77–87.
   PubMed Web of Science ®Google Scholar
• Li SY, Sun R, Wang HX, et al. Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells. J Control Release. 2015;205:7–14.
   PubMed Web of Science ®Google Scholar
• Dwyer RM, Khan S, Barry FP, et al. Advances in mesenchymal stem cell-mediated gene therapy for cancer. Stem Cell Res Ther. 2010;1:25.
   PubMed Web of Science ®Google Scholar
• Pattabiraman DR, Weinberg RA. Tackling the cancer stem cells – what challenges do they pose? Nat Rev Drug Discov. 2014;13:497–512.
   PubMed Web of Science ®Google Scholar
• LaFountaine JS, Fathe K, Smyth HD. Delivery and therapeutic applications of gene editing technologies ZFNs, TALENs, and CRISPR/Cas9. Int J Pharm. 2015;494:180–194.
   PubMed Web of Science ®Google Scholar
• Santarpia L, Bottai G, Kelly CM, et al. Deciphering and targeting oncogenic mutations and pathways in breast cancer. Oncologist. 2016;21:1063–1078.
   PubMed Web of Science ®Google Scholar
• Khan FA, Pandupuspitasari NS, Chun-Jie H, et al. CRISPR/Cas9 therapeutics: a cure for cancer and other genetic diseases. Oncotarget. 2016. DOI:10.18632/oncotarget.9646.
   Web of Science ®Google Scholar
• White MK, Khalili K. CRISPR/Cas9 and cancer targets: future possibilities and present challenges. Oncotarget. 2016;7:12305–12317.
   PubMed Web of Science ®Google Scholar
• Yi L, Li J. CRISPR-Cas9 therapeutics in cancer: promising strategies and present challenges. Biochim Biophys Acta. 2016;1866:197–207.
   PubMed Web of Science ®Google Scholar
• Ge Y, Zhang L, Nikolova M, et al. Strand-specific in vivo screen of cancer-associated miRNAs unveils a role for miR-21(*) in SCC progression. Nat Cell Biol. 2016;18:111–121.
   PubMed Web of Science ®Google Scholar
• Chen B, Chen X, Wu X, et al. Disruption of microRNA-21 by TALEN leads to diminished cell transformation and increased expression of cell-environment interaction genes. Cancer Lett. 2015;356:506–516.
   PubMed Web of Science ®Google Scholar
• Yonezawa A, Dutt S, Chester C, et al. Boosting cancer immunotherapy with anti-CD137 antibody therapy. Clin Cancer Res. 2015;21:3113–3120.
   PubMed Web of Science ®Google Scholar
• McCracken MN, Cha AC, Weissman IL. Molecular pathways: activating T cells after cancer cell phagocytosis from blockade of CD47 “don’t eat me” signals. Clin Cancer Res. 2015;21:3597–3601.
   PubMed Web of Science ®Google Scholar
• Essand M, Loskog AS. Genetically engineered T cells for the treatment of cancer. J Intern Med. 2013;273:166–181.
   PubMed Web of Science ®Google Scholar
• Klebanoff CA, Rosenberg SA, Restifo NP. Prospects for gene-engineered T cell immunotherapy for solid cancers. Nat Med. 2016;22:26–36.
   PubMed Web of Science ®Google Scholar
• Kobold S, Grassmann S, Chaloupka M, et al. Impact of a new fusion receptor on PD-1-mediated immunosuppression in adoptive T cell therapy. J Natl Cancer Inst. 2015;107:djv146.
   Google Scholar
• Iwamura K, Kato T, Miyahara Y, et al. siRNA-mediated silencing of PD-1 ligands enhances tumor-specific human T-cell effector functions. Gene Ther. 2012;19:959–966.
   PubMed Web of Science ®Google Scholar
• Tiptiri-Kourpeti A, Spyridopoulou K, Pappa A, et al. DNA vaccines to attack cancer: strategies for improving immunogenicity and efficacy. Pharmacol Ther. 2016;165:32–49.
   PubMed Web of Science ®Google Scholar
• Melero I, Gaudernack G, Gerritsen W, et al. Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol. 2014;11:509–524.
   PubMed Web of Science ®Google Scholar
• Makkouk A, Weiner GJ. Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge. Cancer Res. 2015;75:5–10.
   PubMed Web of Science ®Google Scholar
• Chiang CL, Coukos G, Kandalaft LE. Whole tumor antigen vaccines: where are we? Vaccines (Basel). 2015;3:344–372.
   PubMed Web of Science ®Google Scholar
• Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity. 2013;39:38–48.
   PubMed Web of Science ®Google Scholar
• Karyampudi L, Lamichhane P, Scheid AD, et al. Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody. Cancer Res. 2014;74:2974–2985.
   PubMed Web of Science ®Google Scholar
• Xie Y, Chen Y, Ahmed KA, et al. Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses. Cancer Gene Ther. 2013;20:590–598.
   PubMed Web of Science ®Google Scholar
• Zheng X, Koropatnick J, Chen D, et al. Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model. Int J Cancer. 2013;132:967–977.
   PubMed Web of Science ®Google Scholar
• Shumway NM, Ibrahim N, Ponniah S, et al. Therapeutic breast cancer vaccines: a new strategy for early-stage disease. BioDrugs. 2009;23:277–287.
   PubMed Web of Science ®Google Scholar
• Ginn SL, Alexander IE, Edelstein ML, et al. Gene therapy clinical trials worldwide to 2012 – an update. J Gene Med. 2013;15:65–77.
   PubMed Web of Science ®Google Scholar
• Domchek SM, Recio A, Mick R, et al. Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance. Cancer Res. 2007;67:10546–10555.
   PubMed Web of Science ®Google Scholar
• Higgins M, Curigliano G, Dieras V, et al. Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive stage II/III breast cancer: a randomized phase I study. Breast Cancer Res Treat. 2017. DOI:10.1007/s10549-017-4130-y.
   PubMedGoogle Scholar
• Lowenfeld L, Mick R, Datta J, et al. Dendritic cell vaccination enhances immune responses and induces regression of HER2pos DCIS independent of route: results of randomized selection design trial. Clin Cancer Res. 2016. DOI:10.1158/1078-0432.ccr-16-1924.
   PubMedGoogle Scholar
• Mittendorf EA, Ardavanis A, Litton JK, et al. Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence. Oncotarget. 2016;7:66192–66201.
   PubMed Web of Science ®Google Scholar
• Mittendorf EA, Clifton GT, Holmes JP, et al. Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients. Ann Oncol. 2014;25:1735–1742.
   PubMed Web of Science ®Google Scholar
• Norell H, Poschke I, Charo J, et al. Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial. J Transl Med. 2010;8:53.
   PubMed Web of Science ®Google Scholar
• Brignone C, Gutierrez M, Mefti F, et al. First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity. J Transl Med. 2010;8:71.
   PubMed Web of Science ®Google Scholar
• Cappello P, Triebel F, Iezzi M, et al. LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice. Cancer Res. 2003;63:2518–2525.
   PubMed Web of Science ®Google Scholar
• Chen G, Gupta R, Petrik S, et al. A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer. Cancer Immunol Res. 2014;2:949–961.
   PubMed Web of Science ®Google Scholar